Vici has proven expertise in producing drug leads and is working to expand its commercial development partnerships for products developed in-house.
Our development pipeline contains many exciting unique barrier-to-entry oral product ANDA opportunities. Our target is to successfully develop and out-license 10 ANDA products a year. We’re actively developing these products while seeking funding, manufacturing or distribution partners. Contact us with your partnership ideas and we can work out a mutually beneficial profit-sharing agreement for these products.
The ANDA pathway is used for the development and approval of generic medicine. Working for our clients, Vici has developed and filed ten (10) ANDAs, eight (8) of which have been approved. Four additional products are on track for ANDA filing by Q1 2020.
The 505(b)(2) NDA pathway allows companies to create new dosage forms, of previously approved molecules, that offer improved convenience, safety, or efficacy at a fraction of the cost of traditional NDAs. Vici is currently developing two products targeting CNS diseases that are on track for 2020 FDA filing.